Responses were excluded when individuals failed both tests; failing one test only was considered as random error.
0.7% of responses were excluded as the treatment plan was not discussed with the patient.
Note: two responses were excluded from the table as they were related to regions where terbuthylazine and hexazinone were not used exclusively.
Twenty eight further responses were excluded from the analysis to correct for outliers in company size and ensure a high degree of comparability among the firms studied.
Missing responses were excluded from the analyses.
All errorful responses were excluded from further analysis.
In analogy to the ERP analysis, events with unspecific slow responses were excluded.
Note that not all 155 samples contributed evaluable data: based on pre-specified filtering criteria, 5 CMV responses, 5 CEF responses and 5 HIV A Gag responses were excluded in the IAVI dataset; 15 CMV responses, 14 CEF responses and 14 Gag responses were excluded in the HVTN dataset.
The operationally defined effects of ANT-R are shown in Table 2. Error trials, which included incorrect and missing responses, were excluded from the calculation of mean RTs.
Incomplete responses were excluded.
